Академический Документы
Профессиональный Документы
Культура Документы
enquanto
agente
terapu2co
Daniel
Gonalves
2013-2014
AHributable
frac2ons
(%)
for
all
cause
deaths
in
40
842
(3333
deaths)
men
and
12
943
(491
deaths)
women.
6%
10%
6%
10%
A
erradicao
da
inac2vidade
Ysica
contribuiria
para
uma
reduo
de
6-10%
nas
principais
doenas
no
transmissveis
Doenas
Cardiovasculares
h7p://stemcells.nih.gov/info/scireport/chapter9.asp
%
recuperao
(trabalho
cardaco)
Intensidade do exerccio
Proteo
contra
a
isquemia
perdura
at
vrios
dias
aps
ul2ma
sesso
Reduo
da
dimenso
da
cicatriz
Previne
a
perda
de
capilares
e
a
formao
de
brose
no
tecido
que
sobrevive
Sedentrio + Isquemia
Treinado + Isquemia
Cardiovascular Rehabilitation
Edited by
Melhoria
da
Funo
Cardaca
Aumento
da
Capacidade
de
Exerccio
Melhoria
da
Qualidade
de
Vida
MCT-
walked
70%
to
75%
of
peak
heart
rate
for
47
minutes
for
12
weeks
AIT-
four
4-minute
intervals
at
90%
to
95%
of
peak
heart
rate
for
12
weeks
TABLE
3.
LV
Volumes
and
Res2ng
Hemodynamics
Control
MCT
AIT
LVDD,
mm
Baseline
67.28.1
Follow-Up
67.812.5
Baseline
69.18.6
Follow-Up
68.26.5
Baseline
66.76.8
Follow-Up
*
59.06.8
LVSD, mm
56.29.2
56.713.7
56.68.8
53.97.4
53.96.7
46.18.2
LVEDV, mL
250.564.4
242.162.3
245.553.1
230.341.0
248.179.6
202.972.0
LVESV, mL
187.853.0
186.658.6
172.948.7
160.634.3
177.472.1
133.957.8
6011
5911
5510
5412
6514
6113
53.415.3
55.013.7
63.512.7
63.115.7
57.114.3
67.019.9
CO, L/min
3.10.6
3.20.5
3.50.9
3.41.1
3.50.5
3.90.6
EF, %
26.28.0
26.69.7
32.84.8
33.55.7
28.07.3
38.09.8
HR
at
rest,
bpm
SV,
mL
*
*
Data
are
meanSD.
LVDD
indicates
LV
diastolic
diameter;
LVSD,
LV
systolic
diameter;
LVEDV,
LV
end-diastolic
volume;
LVESV,
LV
end-systolic
diameter;
HR,
heart
rate;
SV,
stroke
volume;
CO,
cardiac
output;
and
EF,
ejecEon
fracEon.
*Dierent
from
baseline,
P<0.01;
dierent
from
controls
and
moderately
trained,
P<0.02.
Hypertension 2009;53;701-707
6 MWD test
120
100
80
60
40
20
0
Sildenal
Epoprostenol
Iloprost
Bosentan
Drugs+Exercise
Training
N
Engl
J
Med
2005;353:2148
2157;
N
Engl
J
Med
1996;334:296
302;
N
Engl
J
Med
2002;347:322329;
N
Engl
J
Med
2002;346:896903;
CirculaGon
2006;114:1482-1489
JAMA. 2003;290(10):1323-1330
Desaos
h7ps://www.heart.org/HEARTORG/GetngHealthy/PhysicalAcEvity/American-Heart-AssociaEon-RecommendaEons-for-Physical-AcEvity-Infographic_UCM_450754_SubHomePage.jsp
Tipo
Dose
Frequncia
de
toma
Durao
do
tratamento
Objec2vo
terapeu2co
Afeitos
adversos
(que
convm
antecipar)
Subcutnea
Transdrmica
Inalao
Oral
Corresponde
a2vao
do
frmaco
Exerccio
inuencia
os
2
factores
Exercise
intensity
PHYS
THER.
1995;
75:387-396.
70
60
50
40
30
20
10
0
Adeso
Total
Adeso Parcial
No Adeso
Sobretreino
Exerccio)
Agresso)
Leso)das)bras)
msculares)
ac<vam)
Inamao)e)
edema)
Nociceptores)
ac<vados)
Dor)
24C48)
horas)
Imuno-depresso
Estado
pro-
inamatrio
permanente
Imunodepresso
atrasa
ainda
mais
a
regenerao
Maior
suscep2bilidade
a
infeces
Rabdomilise
Manifestaes
clnicas:
mialgia
fraqueza
generalizada
urina
escura
ltrada
do
sangue
ao
nvel
d
Fgado
e
degradada
em
substncias
que
podem
induzir
leso
para
as
clulas
do
Fgado
Revista
Factores
de
Risco,
No12
JAN-MAR
2009
h7p://www.nsc.org/NSC%20Picture%20Library/News/web_graphics/Injury_Facts_37.
Bibliograa
Thomas
L.
Lenz.
PharmacokineEc
Drug
InteracEons
With
Physical
AcEvity.
American
journal
of
lifestyle
medicine
2010
4:
226
American
College
of
Sports
Medicine
(2009).
ACSM's
exercise
management
for
persons
with
chronic
diseases
and
disabili7es
(3rd
ed.).
Champaign,
IL:
Human
KineEcs.
G
E
Moore.
The
role
of
exercise
prescripEon
in
chronic
disease.
Br
J
Sports
Med
2004;38:67.
Mai-Lis
Hellnius,
Carl
Johan
Sundberg.
Physical
acEvity
as
medicine:
Eme
to
translate
evidence
into
clinical
pracEce.
Br
J
Sports
Med
2011;45:158
Catherine
M
Certo.
History
of
Cardiac
RehabilitaEon.
Phys
Ther.
1985;
65:1793-1795.
B.
K.
Pedersen,
B.
SalEn.
Evidence
for
prescribing
exercise
as
therapy
in
chronic
disease.
Scand
J
Med
Sci
Sports
2006:
16
(Suppl.
1):
363